NEW YORK, April 23, 2015 /PRNewswire/ -- Propanc Health Group Corporation (OTCBB: PPCH) is a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic and colorectal cancer. The company lead product includes PRP, a patented formulation consisting of two pro-enzymes, such as trypsinogen and chymotrypsinogen, as well as the enzyme amylase designed to synergistically enhance anti-cancer effects. It is also developing a combination of anti-cancer agents working in combination with pro-enzymes, which enhance PRP's anti-cancer effects. The company was formerly known as Propanc PTY LTD. Propanc Health Group Corporation was founded in 2007 and is based in Melbourne, Australia.
At the beginning, the price was at $0.0014 and with low trading volume. Trading activities have picked up for the stock since March of this year, when it reached a high of over 125 million shares exchanged. Today, the price had a high of $0.47 and a low of just about zero dollars, with a trading volume of about 33 million shares. The average volume traded over the past three months is 18.4 million shares.
According to an experienced analyst, there are several positive signs for the biotech industry in 2015. "Biotech stocks have been on fire since the start of 2015 and there is no sign of the money flows abating anytime soon. The primary driver behind the rise in biotechs may be the Federal Drug Administration (FDA) itself. Last year, it approved 41 new drugs which, according to the organization's website, were the most in nearly 20 years. That figure is up from 27 in 2013---a 51% increase year-over-year."
An analyst brief which covers a brief analysis and analyst recommendation can be viewed in its entirely by using the link below. There is no cost obligation required to view this report.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Stella Nguyen, research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.